Published in PLoS One on September 24, 2009
CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors. Mol Ther Nucleic Acids (2013) 1.45
Generation and characterization of monospecific and bispecific hexavalent trimerbodies. MAbs (2012) 0.91
Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications. Oncoimmunology (2014) 0.85
Engineering T cell function using chimeric antigen receptors identified using a DNA library approach. PLoS One (2013) 0.84
Chimeric antigen receptor-redirected T cells return to the bench. Semin Immunol (2016) 0.81
Selection strategies for anticancer antibody discovery: searching off the beaten path. Trends Biotechnol (2015) 0.76
Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science (1985) 10.42
Making antibodies by phage display technology. Annu Rev Immunol (1994) 5.04
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A (1989) 4.63
Selecting and screening recombinant antibody libraries. Nat Biotechnol (2005) 4.51
Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction. J Virol (1999) 2.15
Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol (1998) 1.96
Replicative adenoviruses for cancer therapy. Nat Biotechnol (2000) 1.89
Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res (1993) 1.87
Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc Natl Acad Sci U S A (2006) 1.30
Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther (2007) 1.25
Lymphatic zip codes in premalignant lesions and tumors. Cancer Res (2006) 1.18
Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci U S A (2008) 1.14
Phage libraries for generation of clinically useful antibodies. Lancet (1994) 1.13
Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol (1996) 1.01
Antibodies and gene therapy: teaching old 'magic bullets' new tricks. Trends Immunol (2004) 0.99
Selection of functional human antibodies from retroviral display libraries. Nucleic Acids Res (2005) 0.97
In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotechnol (1998) 0.97
Expression of carcinoembryonic antigen and its predicted immunoglobulin-like domains in HeLa cells for epitope analysis. Cancer Res (1992) 0.95
A random peptide library fused to CCR5 for selection of mimetopes expressed on the mammalian cell surface via retroviral vectors. J Biol Chem (2005) 0.94
Lentivirus display: stable expression of human antibodies on the surface of human cells and virus particles. PLoS One (2008) 0.90
Pharmacologic suppression of target cell recognition by engineered T cells expressing chimeric T-cell receptors. Cancer Gene Ther (2000) 0.89
Epitope selection from an uncensored peptide library displayed on avian leukosis virus. Virology (2003) 0.85
Genetic approaches for antigen-selective cell therapy. Curr Gene Ther (2001) 0.85
Bacteriophage: tools toward a cell-targeted delivery. Hum Gene Ther (1998) 0.83
Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein. Cancer Gene Ther (2002) 0.80
Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem (2004) 2.33
Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nat Biotechnol (2002) 1.48
CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors. Mol Ther Nucleic Acids (2013) 1.45
Multivalent antibodies: when design surpasses evolution. Trends Biotechnol (2010) 1.28
Lipopolysaccharide activates Toll-like receptor 4 (TLR4)-mediated NF-κB signaling pathway and proinflammatory response in human pericytes. J Biol Chem (2013) 1.23
Long-term in vivo imaging of human angiogenesis: critical role of bone marrow-derived mesenchymal stem cells for the generation of durable blood vessels. Microvasc Res (2007) 1.19
Stathmin and interfacial microtubule inhibitors recognize a naturally curved conformation of tubulin dimers. J Biol Chem (2010) 1.15
Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol (2002) 1.14
Antibody engineering: facing new challenges in cancer therapy. Acta Pharmacol Sin (2005) 1.14
Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds. Stem Cells (2009) 1.09
In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences. PLoS One (2009) 1.02
Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res (2007) 1.02
Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery? Hum Gene Ther (2002) 1.00
Tumor-infiltrating myeloid cells activate Dll4/Notch/TGF-β signaling to drive malignant progression. Cancer Res (2014) 0.99
Antibodies and gene therapy: teaching old 'magic bullets' new tricks. Trends Immunol (2004) 0.99
Selection of functional human antibodies from retroviral display libraries. Nucleic Acids Res (2005) 0.97
Identification and activity of a series of azole-based compounds with lactate dehydrogenase-directed anti-malarial activity. J Biol Chem (2004) 0.96
A novel cell binding site in the coiled-coil domain of laminin involved in capillary morphogenesis. EMBO J (2003) 0.94
Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J Immunol (2003) 0.94
The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies. J Biol Chem (2010) 0.94
Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events. Int J Cancer (2006) 0.92
Generation and characterization of monospecific and bispecific hexavalent trimerbodies. MAbs (2012) 0.91
Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. Cancer Gene Ther (2005) 0.91
Functional improvement of antibody fragments using a novel phage coat protein III fusion system. Biochem Biophys Res Commun (2002) 0.90
Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies. Proc Natl Acad Sci U S A (2013) 0.90
Development of a computer-assisted high-throughput screening platform for anti-angiogenic testing. Microvasc Res (2002) 0.86
Microencapsulation of therapeutic bispecific antibodies producing cells: immunotherapeutic organoids for cancer management. J Drug Target (2014) 0.86
The heterotrimeric laminin coiled-coil domain exerts anti-adhesive effects and induces a pro-invasive phenotype. PLoS One (2012) 0.85
Bacterial tubulin distinct loop sequences and primitive assembly properties support its origin from a eukaryotic tubulin ancestor. J Biol Chem (2011) 0.84
Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. Oncoimmunology (2012) 0.83
Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. Biochem J (2005) 0.83
The therapeutic potential of engineered human neovessels for cell-based gene therapy. Expert Opin Biol Ther (2010) 0.83
Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. Med Oncol (2013) 0.83
Engineering human cells for in vivo secretion of antibody and non-antibody therapeutic proteins. Curr Opin Biotechnol (2011) 0.83
Antibody engineering, virus retargeting and cellular immunotherapy: one ring to rule them all? Curr Gene Ther (2005) 0.82
Antibody gene therapy: getting closer to clinical application? Curr Gene Ther (2013) 0.81
Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I. Immunology (2006) 0.80
The extracellular matrix: a new turn-of-the-screw for anti-angiogenic strategies. Trends Mol Med (2003) 0.80
Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein. Cancer Gene Ther (2002) 0.80
Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells. Cancer Gene Ther (2005) 0.79
Engineered human tumor xenografts with functional human vascular networks. Microvasc Res (2010) 0.79
Efficient production of single-chain fragment variable-based N-terminal trimerbodies in Pichia pastoris. Microb Cell Fact (2014) 0.78
The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice. Mol Ther (2012) 0.78
Magnetic isolation of Plasmodium falciparum schizonts iRBCs to generate a high parasitaemia and synchronized in vitro culture. Malar J (2014) 0.78
Basement membrane-rich organoids with functional human blood vessels are permissive niches for human breast cancer metastasis. PLoS One (2013) 0.77
Adenovirus E1a protein enhances the cytotoxic effects of the herpes thymidine kinase-ganciclovir system. Cancer Gene Ther (2003) 0.76
Generation of non-permissive basement membranes by anti-laminin antibody fragments produced by matrix-embedded gene-modified cells. Cancer Immunol Immunother (2003) 0.76
Tumor cell surface display of immunoglobulin heavy chain Fc by gene transfer as a means to mimic antibody therapy. Hum Gene Ther (2005) 0.76
In vivo selection of tumor-specific antibodies. Oncotarget (2013) 0.76
Bacterial secretion of soluble and functional trivalent scFv-based N-terminal trimerbodies. AMB Express (2015) 0.75
Comment on "Production of multivalent protein binders using a self-trimerization collagen-like peptide scaffold". FASEB J (2008) 0.75
Functionally fused antibodies--a novel adjuvant fusion system. J Immunol Methods (2008) 0.75
Establishment of an immortalized PARP-1-/- murine endothelial cell line: a new tool to study PARP-1 mediated endothelial cell dysfunction. J Cell Biochem (2005) 0.75
Antibody-based antiangiogenic cancer therapy. Expert Opin Ther Targets (2005) 0.75